Patients with primary systemic amyloidosis (AL) often experience bleeding, and we report a newly recognized coagulation abnormality in AL. Of 103 patients with primary systemic AL studied over 2 years, 41 had prolongation of the thrombin time (range, 25 to 46 seconds; normal, <22 seconds) and reptilase time (range, 17 to 39 seconds; normal, 14 to 16 seconds). The fibrinogen from the plasma of 36 patients was precipitated by p-alanine and diluted to a concentration of approximately 200 mg/dL. The thrombin times of the precipitated fibrinogens were normal in 34 patients, implying that an inhibitor was responsible for the abnormal tests. We examined the coagulation studies of 41 patients with AL and investigated the nature of the prolongation of the thrombin time by partially purifying the fibrinogen of 36 of these patients.
Patients with primary systemic amyloidosis (AL) often experience bleeding, and we report a newly recognized coagulation abnormality in AL. Of 103 patients with primary systemic AL studied over 2 years, 41 had prolongation of the thrombin time (range, 25 to 46 seconds; normal, <22 seconds) and reptilase time (range, 17 to 39 seconds; normal, 14 to 16 seconds). The fibrinogen from the plasma of 36 patients was precipitated by p-alanine and diluted to a concentration of approximately 200 mg/dL. The thrombin times of the precipitated fibrinogens were normal in 34 patients, implying that an inhibitor was responsible for the abnormal tests. The addition of patient fibrinogen-free plasma to normal plasma ATIENTS WITH PRIMARY systemic amyloidosis P (AL) may experience bleeding. Much attention has been focused on the presence of abnormal prothrombin times and associated factor X deficiencies,' but we have recognized a far more common coagulation abnormality in amyloidosis-a prolonged thrombin time. Prolonged thrombin times associated with acquired factor X deficiency have been described in only a few Prolonged thrombin times and normal reptilase times have been reported in patients with another related dysproteinemia (multiple myeloma) and a heparan sulfate proteoglycan anticoagulant has been isolated and characterized' Abnormal and inhibited thrombin times associated with abnormal reptilase times often are interpreted as representing dysfibrinogenemia, as frequently seen in patients with severe liver di~ease.~. ' We examined the coagulation studies of 41 patients with AL and investigated the nature of the prolongation of the thrombin time by partially purifying the fibrinogen of 36 of these patients.
SELECTION OF PATIENTS
Patients seen in the Dysproteinemia Clinic at the Mayo Clinic are routinely screened for coagulation abnormalities, most often for factor X deficiency. Over 2 years, 103 patients with primary systemic AL were studied in the coagulation laboratory. All of these patients had thrombin times determined. Forty-one patients with a prolonged thrombin time ( > 5 seconds in excess of control) and the diagnosis of AL who were seen between April 8,1986 , and March 28, 1988, were studied. A sufficient sample was available in 36 patients, and the fibrinogen was isolated from the plasma. The fibrinogen of 25 controls also was isolated.
MATERIALS AND METHODS
Venous blood was collected with a plastic syringe and dispensed into a plastic vial containing trisodium citrate and aprotinin (final concentration 0.38% and 260 KIU/mL, respectively) (aprotinin from Trasylol, Mobay Chemical Corporation, New York, NY). Blood was centrifuged at 4°C at 1,700g for 10 minutes. Platelet-poor plasma (PPP) was removed and placed at 4°C if tested the same day or frozen at -20°C for later testing. The cellular fraction was strained through Collection and handling of specimen.
prolonged the thrombin times, and this result confirmed the presence of an inhibitor. The inhibitor is more likely to be present in patients with nephrotic syndrome (20 of our patients) and congestive heart failure (six). A circulating monoclonal protein (24 patients), the presence of amyloid liver involvement (eight), and the presence of amyloid neuropathy (nine) were not predisposing factors. Only one patient had deficiency of factor x. We conclude that inhibition of fibrinogen conversion to a fibrin clot rather than dysfibrinogenemia is the cause of the prolonged thrombin time in primary systemic AL.
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gauze. The sample was rejected if visible clots were present. Routine coagulation assays, including thrombin time, prothrombin time (Thromboplastin C; Dade, Miami, FL), activated partial thromboplastin time (Organon Technica, Durham, NC), reptilase time, protamine gel, and fibrinogen determination, were performed as previously described."
One milliliter of 6.0 mol/L p-alanine was added to 2.0 mL plasma in plastic test tubes. The sample was gently vortexed and placed on melting ice for 30 minutes. It then was centrifuged for 20 minutes at 4°C at 8,700g. The supernatant was discarded. The precipitate was rinsed once with 0.017 mol/L imidazole, 0.10 N NaC1, 0.05 mollL aminocaproic acid, pH 7.4: This buffered saline, 1.1 mL, was added to the precipitate, which was then warmed to 35°C for 5 minutes and dissolved. Fibrinogen composed approximately 50% of the dissolved protein, based on residual absorbance after clotting 1 mL protein solution with 10 units bovine thrombin (n = 5). Using an extinction coefficient of 1.64" for 0.1% (100 mg/dL) solution of fibrinogen at 280 nm, and because 50% of total absorbance was previously shown to be fibrinogen, the protein solution was diluted with buffered saline to 6.6 absorbance units. This dilution yields approximately 200 mg/dL fibrinogen. Bovine thrombin (Parke-Davis, division of WarnerLambert, Morris Plains, NJ) was diluted in buffered saline to give a control PPP thrombin time of 20 2 0.5 seconds ( 2 2 SD) (approximately 15 IJ.L of thrombin in 10 mLof buffered saline)."," Duplicate thrombin times were determined on each PPP and diluted fibrinogen isolate. The precision of duplicate thrombin times performed in the assays was t0.32 second (n = 25).
Normal plasma and amyloid PPP were depleted of fibrinogen with 0.5% bentonite." Fifty microliters of a 100 mg/mL suspension of bentonite (Sigma, St Louis, MO) in buffered saline was added to 1 mL of plasma and placed on a rocking platform for 30 minutes at room temperature. Samples were centrifuged at 1,OOOg for 15 minutes and the supernatants were tested for the presence of inhibitor. Equal volumes of normal supernatant or amyloid supernatant were mixed with normal GASTlNEAU ET AL plasma and allowed to incubate at room temperature for 30 minutes. and thrombin times were determined.
Plasma was depleted of fibrinogen by heating in a 56°C waterbath for 4.5 minutes. Samples were centrifuged and tested for the presence of inhibitor as described above.
The mean thrombin time of the normal PPP was 20.9 seconds (2 SD range, 17.7 to 24.1 seconds; 1 SD. 1.6 seconds; n = 35). The mean thrombin time of the normal isolated fibrinogen was 17.4 seconds (2 SD range, 14.9 to 19.9 seconds; 1 SD. 1.25 seconds; n = 35).
A normal result is a purified fibrinogen thrombin time less than or equal to the normal PPP thrombin time (generally 18 to 21 seconds). A normal isolated fibrinogen thrombin time and prolonged PPP thrombin time are consistent with the presence of an inhibitor. The prolongation of both clotting times is consistent with a dysfibrinogcnemia.
fnrep"ion.
RESULTS
The fibrinogcn from the plasma of 36 patients with abnormal thrombin timcs was prccipitatcd by p-alaninc and diluted to a conccntration of approximately 200 mg/dL. Thc thrombin times of the prccipitatcd fibrinogcns wcrc normal in 34 of thc 36 patients. implying thc presence of an inhibitor.
Thrcc patients with known dysfibrinogcnemia (one plasma samplc was kindly provided by Dr Douglas Triplctt, Muncic, IN) wcrc studicd. The isolated fibrinogcns of thcsc patients produccd prolongcd thrombin times (Fig 1) . All wcrc substantially morc prolongcd than the only two amyloid-associatcd fibrinogcns that did not correct to the normal range.
Normal and amyloid PPPs were depleted of fibrinogen using 0.5% bcntonitc or heating to 56°C for 4.5 minutcs. Aftcr ccntrifugation, the supcrnatants wcrc mixcd with normal PPP and thrombin timcs wcrc dctcrmincd. Supematant from thc thrcc amyloid plasmas prolongcd the thrombin timc (Tablc 1).
The thrombin timc waq the only coagulation test result that was consistcntly abnormal: prolongcd in 36 of thc 41 paticnts studicd (Tablc 2). Clottablc fibrinogen lcvcls (biuret method) generally were clcvatcd (range, 210 to 1,190 mg/dL; mcdian, 636 mg/dL) in paticnts whosc thrombin timc was prolongcd. No paticnt had hypofibrinogcn- cmia. Consistcntly ncgativc protamine gel tests indicatcd the absence of active disseminated intravascular coagulation. The rcptilasc timc was consistcntly clcvatcd (rangc, 17 to 39 seconds; median, 24 scconds; control, 15 seconds) in direct proportion to thc prolongation of thc thrombin timc, suggesting that a heparin-likc inhibitor was not present.
The clinical abnormalitics arc listcd in Tablc 3. Thc most common findings wcrc abnormal cchocardiograms and nephrotic syndromc. Although thcsc wcrc thc most common, no corrclation with thc dcgrcc of prolongation of thc thrombin timc was found. A circulating monoclonal protein was seen in 24 of the patients. The results of immunoelectrophoresis arc shown in Tabk 4. The scrum monoclonal protcin was gencrally small in amount and cxcccdcd 1 g/dL in only ninc of the paticnts and cxcccdcd 2 g/dL in only one. Ninc paticnts had a scrum monoclonal pmtcin and did not havc associated congestive hcart failurc or ncphrotic syndromc. Thc thrombin timc in thcsc ninc paticnts rangcd from 19.7 to 41.8 scconds (median, 22.3 scconds). In thc fivc patients without a monoclonal scrum protcin and without hcart failure or nephrotic syndromc. thc thrombin timc rangcd from 20 to 26.3 scconds (mcdian, 23.4 scconds). Only onc paticnt had a prolongcd prothrombin timc (22.2 seconds), and this paticnt had a factor X lcvcl of 6%. Thc factor X lcvcls wcrc not dcprcssed bclow 40% in any of thc othcr patients.
Figurc 1 shows the results of thc thrombin timc bcforc and aftcr thc fibrinogcn was purified. Of thc 36 paticnts whosc thrombin timc was prolongcd 2 scconds grcatcr than control, thc thrombin timc normalized in 34. Thc thrombin timc was shortcncd a mcdian of 8 scconds in thc 36 whosc thrombin timc was abnormal. In a control group of normals, purification of the fibrinogcn rcsultcd in a median shortcning of the thrombin timc by 4 seconds.
Ncithcr incrcasing thc protcin canccntration with bovinc scrum albumin nor adding fibrin split products (Dadc) rcsultcd in prolongation of the thrombin timc (data not 
DISCUSSION
The thrombin time can be prolonged for several reasons, including (1) the presence of heparin, ( 2 ) hypofibrinogenemia, (3) dysfibrinogenemia, (4) circulating anticoagulants, and (5) the presence of fibrin or fibrinogen split products. Differentiation of most of these causes is not difficult through the quantitative determination of the fibrinogen value and of the reptilase time to exclude heparin-type anticoagulants and through assays for fibrin degradation products and fibrin monomers. However, generally dysfibrinogenemia is diagnosed through exclusion of other causes because no simple in vitro test exists to confirm the presence of a structurally abnormal fibrinogen. The cause of prolonged thrombin times in AL has been previously attributed to the presence of an abnormal fibrinogen. These studies report prolongation of prothrombin, activated partial thromboplastin, or thrombin times, but no mixing studies or purification of fibrinogen was reported.13, '4 Bleeding in amyloidosis is multifactorial. Vascular infiltration of amyloid fibrils disrupts vascular integrity and has been associated with recurrent gastrointestinal hemorrhage.15 Coagulation factor deficiencies have been well established, and the apparent ability of amyloid fibrils to bind factor X has been Only one of our 41 patients had a prothrombin time greater than 2 seconds beyond control, and that patient had a factor X level of 6%; thus, factor X deficiency is rarely associated with an abnormal thrombin time. Severe liver involvement by amyloid causes deficiencies of many hepatically synthesized clotting factors and can imitate disseminated intravascular coagulation and fibrinolysis through failure of hepatic clearance of fibrin split products. Prolongation of the thrombin time in severe nonamyloid liver disease is due to abnormal fibrinogen sialic acid content resulting in abnormal fibrin monomer polymerization. Increased sialyltrans- Nephrotic syndrome ( > 3 g proteid24 h)
Renal insufficiency (creatinine, > 1.5 mg/dL) Hepatomegaly (>2 cm below costal margin) 8 20 8
Age range was 42 to 84 years (median, 52 years).
ferase activity produces a fibrinogen similar to fetal fibrinogen.6s7 Adding excess calcium characteristically shortens the thrombin time.
The presence of a serum monoclonal protein (usually associated with multiple myeloma) has been associated with heparin or heparin-like circulating anticoagulants? The prolongation of the thrombin time can be partially reversed with protamine. The thrombin time may also be shortened by the effects of chemotherapy, as we recently observed in a patient with a heparan-like inhibitor. These patients may experience severe bleeding, especially from the gastrointestinal tract."
Our data suggest that the monoclonal protein in our patients did not cause the abnormal thrombin time because the thrombin times were not different between those amyloid patients with and those without a serum monoclonal protein. The thrombin time abnormality did not have any effect on the likelihood of clinical bleeding or thrombosis.
Hypofibrinogenemia may result from defective production of fibrinogen, as may be seen in severe liver disease?" Total fibrinogen concentrations were preserved in our patients despite significant hepatomegaly in six. In fact, all patients tested had fibrinogen values greater than 200 mg/dL.
Circulating anticoagulants of the lupus-type were not specifically sought, and although some patients with monoclonal proteins have a lupus-type activity, these patients are rare, comprising only 10 of 219 such patients in our laboratory. None of these patients had amyloidosis.21
Butler and Baldwin' described a patient with factor X deficiency who also had a prolonged thrombin time, and in a review of the literature they found that eight of 14 patients had either a thrombin time greater than 1.5 times control or a prolonged thrombin time that was not corrected in vitro when mixed with normal plasma. They postulated, as have others: that inhibitors may be present, 
